TP53 and prognosis in mCRPC survival: biology or coincidence?
Rebello, R Oing, C Gillessen, Silke Bristow, Robert G
Rebello, R
Oing, C
Gillessen, Silke
Bristow, Robert G
Citations
Altmetric:
Abstract
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al.
Description
Date
2018
Publisher
Collections
Keywords
Type
Article
Citation
Rebello RJ, Oing C, Gillessen S, Bristow RG. TP53 and prognosis in mCRPC survival: biology or coincidence. Clin Cancer Res. 2019.